PriceTargets.com logo

Acelyrin - SLRN Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $11.50
  • Forecasted Upside: 122.87%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$5.16 As of 11/14/2024 01:00 AM ET
▼ -0.82 (-13.71%)

This chart shows the closing price for SLRN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Acelyrin Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SLRN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SLRN

Analyst Price Target is $11.50
▲ +122.87% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Acelyrin in the last 3 months. The average price target is $11.50, with a high forecast of $20.00 and a low forecast of $6.00. The average price target represents a 122.87% upside from the last price of $5.16.

This chart shows the closing price for SLRN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 6 polled investment analysts is to moderate buy stock in Acelyrin. This rating has held steady since June 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
2/18/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
5/18/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
8/16/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/15/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/14/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/14/2024HC WainwrightBoost TargetNeutral ➝ Neutral$6.00 ➝ $8.00
10/16/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$13.00 ➝ $15.00
8/19/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$13.00 ➝ $6.00
8/14/2024Piper SandlerLower TargetOverweight ➝ Overweight$68.00 ➝ $20.00
8/14/2024HC WainwrightDowngradeBuy ➝ Neutral$18.00 ➝ $6.00
7/8/2024Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$13.00 ➝ $13.00
5/22/2024HC WainwrightBoost TargetBuy ➝ Buy$16.00 ➝ $18.00
5/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$16.00
5/9/2024HC WainwrightLower TargetBuy ➝ Buy$28.00 ➝ $18.00
4/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$28.00
3/21/2024Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$11.00 ➝ $13.00
3/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00
12/13/2023Wells Fargo & CompanyInitiated CoverageEqual Weight$11.00
12/8/2023CitigroupInitiated CoverageNeutral$8.00
11/29/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$19.00 ➝ $13.00
11/28/2023Jefferies Financial GroupLower TargetBuy ➝ Buy$15.00 ➝ $12.00
11/28/2023HC WainwrightReiterated RatingBuy ➝ Buy$30.00
9/13/2023Morgan StanleyDowngradeOverweight ➝ Equal Weight$39.00 ➝ $19.00
9/12/2023HC WainwrightLower TargetBuy ➝ Buy$44.00 ➝ $30.00
9/5/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$29.00 ➝ $39.00
9/5/2023HC WainwrightInitiated CoverageBuy$44.00
5/30/2023Morgan StanleyInitiated CoverageOverweight
5/30/2023TD CowenInitiated CoverageOutperform
5/30/2023Jefferies Financial GroupInitiated CoverageBuy$31.00
5/30/2023Piper SandlerInitiated CoverageOverweight$68.00
(Data available from 11/15/2019 forward)

News Sentiment Rating

0.57 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/18/2024
  • 6 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/17/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/17/2024
  • 4 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/16/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/15/2024
  • 8 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/15/2024
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/14/2024

Current Sentiment

  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Acelyrin logo
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.
Read More

Today's Range

Now: $5.16
Low: $5.01
High: $6.19

50 Day Range

MA: $5.39
Low: $4.24
High: $6.48

52 Week Range

Now: $5.16
Low: $3.36
High: $9.25

Volume

1,203,985 shs

Average Volume

1,028,285 shs

Market Capitalization

$515.01 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.98

Frequently Asked Questions

What sell-side analysts currently cover shares of Acelyrin?

The following Wall Street sell-side analysts have issued research reports on Acelyrin in the last year: Citigroup Inc., HC Wainwright, Jefferies Financial Group Inc., Morgan Stanley, Piper Sandler, and Wells Fargo & Company.
View the latest analyst ratings for SLRN.

What is the current price target for Acelyrin?

0 Wall Street analysts have set twelve-month price targets for Acelyrin in the last year. Their average twelve-month price target is $11.50, suggesting a possible upside of 122.9%. Piper Sandler has the highest price target set, predicting SLRN will reach $20.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $6.00 for Acelyrin in the next year.
View the latest price targets for SLRN.

What is the current consensus analyst rating for Acelyrin?

Acelyrin currently has 3 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for SLRN.

What other companies compete with Acelyrin?

Other companies that are similar to Acelyrin include Longboard Pharmaceuticals, Scholar Rock, Akero Therapeutics, Vericel and NewAmsterdam Pharma. Learn More about companies similar to Acelyrin.

How do I contact Acelyrin's investor relations team?

The company's listed phone number is 805-730-0360 and its investor relations email address is [email protected]. The official website for Acelyrin is www.acelyrin.com. Learn More about contacing Acelyrin investor relations.